ASA issues top five 'Choosing wisely' recommendations

ASA issues top five <i>Choosing wisely</i> recommendations

(HealthDay)—The top five anesthesiology-related pain medicine issues that physicians and patients should question have been released by the American Society of Anesthesiologists (ASA) as part of the Choosing Wisely campaign.

The ASA Committee on Pain Medicine submitted potential recommendations and voted on which issues should be included in the top five. Supporting evidence was identified from literature searches.

The top five recommendations include: (1) opioid analgesics should not be prescribed as first-line therapy for treatment of non-cancer pain; (2) should not be prescribed as long-term treatment for chronic non-cancer pain treatment until the risks have been considered and discussed with the patient; (3) imaging studies such as , computed tomography, or X-ray should be avoided for acute without specific indications; (4) intravenous sedation should not be used as a default practice for diagnostic and therapeutic nerve blocks or joint injections; and (5) irreversible interventions for non-cancer pain that carry considerable costs and/or risks should be avoided.

"As leaders in patient safety, physician anesthesiologists want the most effective tests and treatments for our patients and we want them to be used appropriately," Jane C.K. Fitch, M.D., president of the ASA, said in a statement. "ASA has taken the lead in improving patient safety related to anesthesiology and ."

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

SGO issues top five Choosing Wisely recommendations

Nov 06, 2013

(HealthDay)—The top five gynecologic oncology-related issues that physicians and patients should question have been released by the Society of Gynecologic Oncology (SGO) as part of the Choosing Wisely campai ...

AAFP issues top five 'choosing wisely' recommendations

Feb 26, 2013

(HealthDay)—The top five primary care issues that patients and physicians should question have been released by the American Academy of Family Physicians (AAFP) as part of the Choosing Wisely Campaign.

Recommended for you

Supercomputers link proteins to drug side effects

7 hours ago

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

14 hours ago

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments